EU/3/07/442: Orphan designation for the treatment of diffuse large B-cell lymphoma

Enzastaurin hydrochloride

Table of contents


Please note that this product was withdrawn from the Union Register of orphan medicinal products in June 2023 on request of the Sponsor.

On 20 March 2007, orphan designation (EU/3/07/442) was granted by the European Commission to Eli Lilly Nederland B.V., The Netherlands, for enzastaurin hydrochloride for the diffuse large B cell lymphoma.

Key facts

Active substance
Enzastaurin hydrochloride
Intended use
Treatment of diffuse large B-cell lymphoma
Orphan designation status
EU designation number
Date of designation

Dlrc Pharma Services Limited
Chesterfield House
Ashford A67 WR29
Co. Wicklow
Tel: + 35340478808

Update history

September 2023The product was withdrawn from the Union Register of orphan medicinal products on request of the Sponsor.
October 2020The sponsorship was transferred to Dlrc Pharma Services Limited, Ireland.
February 2016The sponsorship was transferred to Isabelle Ramirez, Germany.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating